Insider Trading › CTRX › Insiders
CTRX
CTRX·Insider activity
—
No end-of-day price on record
CTRX
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CTRXS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
No open-market insider purchases or sales of CTRX were filed in the last 180 days. Newest filing Mar 14, 2012 (14 years ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by CTRX insiders · Form 4 · last two years
No open-market insider buys or sells in the last two years.
On Record
$0Purchases · 180 days
$0Sales · 180 days
4Open-market transactions on record
0Insiders filing · 180 days
Purchases (code P) and sales (code S) of CTRX common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
4 on record · newest trade first
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| Chiesi Farmaceutici SpA10% owner | Purchase | +3,400 | n/c | — | 14.2Mdirect | Mar 12, 2012 | Mar 14, 2012 | Form 4 ↗ |
| Feldman ThomasChief Business Officer | Sale | −12.5K | $11.12 | $139K | 115.0Kdirect | Feb 22, 2006 | Feb 24, 2006 | Form 4 ↗ |
| Feldman ThomasChief Business Officer | Sale | −7,500 | $11.00 | $83K | 127.5Kdirect | Feb 22, 2006 | Feb 24, 2006 | Form 4 ↗ |
| Feldman ThomasChief Business Officer | Sale | −15.0K | $11.00 | $165K | 110.0Kdirect | Feb 22, 2006 | Feb 24, 2006 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →